Is Pfizer Doing Enough to Change?

Pfizer (NYSE: PFE) is experiencing difficulties with regards to patent expiries. But is it doing enough to combat this?

Mar 2, 2014 at 12:30PM

Having had a disappointing 2013, where shares lagged the S&P 500 by 9% (up 23% versus a gain of 32% for the index), Pfizer (NYSE:PFE) has made an encouraging start to 2014. Indeed, shares are up more than 5% since the start of the year, while the S&P 500 is up less than 1%.

However, fourth-quarter results released by Pfizer highlighted the problems the business is currently experiencing. The main one, of course is the loss of patents on key blockbuster drugs that are open to competition from generics. The effects of this are significant, with Pfizer expected to deliver a fall in revenue in 2014 and in 2015 as a number of key drugs see sales fall because of copycat drugs.

The response from Pfizer is, as with many of its peers, to seek replacements for the drugs that are off-patent or will soon be off-patent. However, is Pfizer doing enough to counter the challenge presented by patent expiries and generic drugs? More importantly, can it continue to outperform the S&P 500 through 2014?

Mixed news
News flow surrounding Pfizer's pipeline in 2014 has been mixed. For instance, dacomitinib, Pfizer's potential treatment for an advanced form of lung cancer, missed its main goals in two late-stage studies in late January. The drug failed to show a statistically significant improvement in progression-free survival in a study comparing it with the treatment erlotinib. Furthermore, it also missed the aim of prolonging overall survival when compared with a placebo in the second study. The results from a third study are expected later this year or early next year.

However, not all trials are bound to be a success, and there have been positive developments for Pfizer, too. For example, it remains positive regarding its breast cancer drug, palbociclib, as well as a pneumonia vaccine called Prevnar 13. Indeed, the latter was reported to have met its objectives just last week in a trial that tested the effectiveness of the vaccine in 85,000 patients aged 65 or older against pneumonia. Meanwhile, Pfizer's breast cancer drug has the potential to add up to $3 billion per annum in revenues if it the FDA approves it. So while news has been mixed, there does seem to be light at the end of the tunnel for Pfizer.

Pfizer is not alone
Of course, other major pharmaceutical stocks are also experiencing patent expiries and are attempting to overcome the threat posed by generic competition. For instance, Bristol-Myers Squibb (NYSE:BMY) last week announced that the FDA has approved its drug, Myalept, to treat potentially fatal disorders involving the loss of body fat. The drug will be used as a replacement therapy to treat complications caused by leptin hormone deficiency in patients with congenital generalized lipodystrophy, which can ultimately lead to pancreatitis and diabetes.

In addition, sector peer Eli Lilly (NYSE:LLY) saw net profit fall by 12% in the fourth quarter of 2013. However, it's making solid progress and announced last week that a study comparing its drug for type 2 diabetes was comparable to a drug produced by Novo Nordisk in reducing blood sugar levels. It is forecast that the drug, dulaglutide, could net Eli Lilly up to $2 billion in additional revenue per year, subject, of course, to FDA approval.

Looking ahead
So while Pfizer is forecast to experience a fall in revenue of around 4% between 2013 and 2015, it's making the right moves to grow the top line in the long run. Sure, not all of the drugs currently in its pipeline are likely to be approved, and there will be disappointing news flow along the way, but it seems to have enough potential in its pipeline to deliver growth over the medium to long term. The market seems to be warming to this potential (as evidenced by its share price outperformance in 2014), and the rest of the year could prove to be a strong one for Pfizer.

2014 could be a strong year for this stock, too
As Pfizer shows, there's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Peter Stephens and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers